{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:04:53Z","timestamp":1788206693069,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure is among the most frequent complications of patients on long-term haemodialysis. The benefits of renin\u2013angiotensin system (RAS) blockade on the outcomes of these patients have yet to be determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a nationwide observational study using data from the Taiwan National Health Insurance claims database, between 1999 and 2010. We enrolled patients aged \u226535 years with new-onset heart failure [diagnosed by International Classification of Diseases, 9th revision, clinical modification (ICD-9-CM) codes] under treatment with medications. New users of a RAS blocker (RASB; i.e. an ACE inhibitor or an ARB used as monotherapy or dual therapy) were selected to compare with non-RASB users. We used Cox proportional hazards regression with and without propensity score adjustment to compare the risk of 3-year all-cause and cardiovascular mortality. Stratified analyses and RASB therapy duration as a time-dependent covariate were also performed. In all, 4771 were treated with an RASB (n = 3024) or without an RASB (n = 1747). RASB users had a higher prevalence of hypertension and diabetes, and a higher number of hospitalization. Among RASB users, 1148 deaths (38.0%) occurred during 5272 person-years of follow-up compared with 734 deaths (42.0%) among non-RASB users during 2683 person-years of follow-up. Three-year mortality rates were 45.4% and 49.1% for patients receiving and those not receiving an RASB, respectively (log-rank test, P &amp;lt; 0.001). Adjusted hazard analysis revealed that RASB therapeutic effects remained significant on all-cause [hazard ratio (HR) 0.8; 95% confidence interval (CI) 0.72\u20130.89; P &amp;lt; 0.001] and cardiovascular mortality (HR 0.76; 95% CI 0.64\u20130.90; P &amp;lt; 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RASB therapy reduced all-cause and cardiovascular mortality in heart failure patients on long-term haemodialysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hft082","type":"journal-article","created":{"date-parts":[[2013,5,13]],"date-time":"2013-05-13T20:35:18Z","timestamp":1368477318000},"page":"1194-1202","source":"Crossref","is-referenced-by-count":21,"title":["Renin\u2013Angiotensin System Blockade in Heart Failure Patients on Long-Term Haemodialysis in Taiwan"],"prefix":"10.1093","volume":"15","author":[{"given":"Chao-Hsiun","family":"Tang","sequence":"first","affiliation":[{"name":"School of Health Care Administration, Taipei Medical University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tso-Hsiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University , Taipei ,","place":["Taiwan"]},{"name":"Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, Fu-Jen Catholic University , New Taipei City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang-Ye","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University , Taipei ,","place":["Taiwan"]},{"name":"Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chih","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Health Care Administration, Taipei Medical University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Mou","family":"Sue","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University , Taipei ,","place":["Taiwan"]},{"name":"Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"2026011921160481000_ejhfhft082-bib-0001","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfn406","article-title":"Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance","volume":"23","author":"Yang","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026011921160481000_ejhfhft082-bib-0002","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1111\/j.1523-1755.2004.00657.x","article-title":"Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study","volume":"65","author":"Cheung","year":"2004","journal-title":"Kidney Int"},{"key":"2026011921160481000_ejhfhft082-bib-0003","first-page":"1343","article-title":"The renal patient with coronary artery disease: current concepts and dilemmas","volume":"44","author":"Gupta","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026011921160481000_ejhfhft082-bib-0004","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1053\/ajkd.2001.28588","article-title":"A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients","volume":"38","author":"Stack","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2026011921160481000_ejhfhft082-bib-0005","first-page":"803","article-title":"Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011921160481000_ejhfhft082-bib-0006","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026011921160481000_ejhfhft082-bib-0007","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2026011921160481000_ejhfhft082-bib-0008","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusu","year":"2003","journal-title":"Lancet"},{"key":"2026011921160481000_ejhfhft082-bib-0009","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"2026011921160481000_ejhfhft082-bib-0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1291\/hypres.29.253","article-title":"Effects of imidapril on left ventricular mass in chronic hemodialysis patients","volume":"29","author":"Matsumoto","year":"2006","journal-title":"Hypertens Res"},{"key":"2026011921160481000_ejhfhft082-bib-0011","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1053\/ajkd.2002.36340","article-title":"ACE inhibitors and survival of hemodialysis patients","volume":"40","author":"Efrati","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2026011921160481000_ejhfhft082-bib-0012","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis\u2014a randomized study","volume":"21","author":"Takahashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2026011921160481000_ejhfhft082-bib-0013","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2026011921160481000_ejhfhft082-bib-0014","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2215\/CJN.07831109","article-title":"Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis","volume":"5","author":"Tai","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026011921160481000_ejhfhft082-bib-0015","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0272-6386(03)00359-7","article-title":"Heart failure as a cause for hospitalization in chronic dialysis patients","volume":"41","author":"Trespalacios","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026011921160481000_ejhfhft082-bib-0016","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"2026011921160481000_ejhfhft082-bib-0017","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ahj.2011.05.004","article-title":"Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis","volume":"162","author":"Chang","year":"2011","journal-title":"Am Heart J"},{"key":"2026011921160481000_ejhfhft082-bib-0018","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinternmed.2012.139","article-title":"Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study","volume":"172","author":"Bajaj","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026011921160481000_ejhfhft082-bib-0019","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ki.2011.228","article-title":"Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients","volume":"80","author":"Chan","year":"2011","journal-title":"Kidney Int"},{"key":"2026011921160481000_ejhfhft082-bib-0020","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011921160481000_ejhfhft082-bib-0021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2026011921160481000_ejhfhft082-bib-0022","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.jhealeco.2008.03.002","article-title":"Hospital ownership and performance: evidence from stroke and cardiac treatment in Taiwan","volume":"27","author":"Lien","year":"2008","journal-title":"J Health Econ"},{"key":"2026011921160481000_ejhfhft082-bib-0023","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/j.ajkd.2006.06.006","article-title":"Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients","volume":"48","author":"Roy","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2026011921160481000_ejhfhft082-bib-0024","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-9343(01)01068-3","article-title":"Renin\u2013angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients","volume":"112","author":"Knoll","year":"2002","journal-title":"Am J Med"},{"key":"2026011921160481000_ejhfhft082-bib-0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2026011921160481000_ejhfhft082-bib-0026","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026011921160481000_ejhfhft082-bib-0027","first-page":"309","article-title":"The influence of ACE-inhibition on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure","volume":"42","author":"Roithinger","year":"1994","journal-title":"Clin Nephrol"},{"key":"2026011921160481000_ejhfhft082-bib-0028","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","author":"K\/DOQI Workgroup","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2026011921160481000_ejhfhft082-bib-0029","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jacc.2006.07.073","article-title":"Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure","volume":"49","author":"Costanzo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026011921160481000_ejhfhft082-bib-0030","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jama.2012.452","article-title":"Association of treatment with losartan vs candesartan and mortality among patients with heart failure","volume":"307","author":"Svanstrom","year":"2012","journal-title":"JAMA"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhft082","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhft082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hft082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hft082","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/10\/1194\/66443452\/eurjhf_15_10_1194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/10\/1194\/66443452\/eurjhf_15_10_1194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:19:41Z","timestamp":1768875581000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/15\/10\/1194\/8428785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,1,27]]},"published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hft082","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,10]]},"published":{"date-parts":[[2013,10,1]]}}}